Tags

Type your tag names separated by a space and hit enter

The efficacy and safety of moxibustion for chronic fatigue syndrome: A protocol for systematic review and meta-analysis.
Medicine (Baltimore). 2021 May 07; 100(18):e25742.M

Abstract

BACKGROUND

The pathogenesis of chronic fatigue syndrome (CFS) is not clear. The main purpose of treatment is to improve autoimmune function and relieve fatigue symptoms. Moxibustion is often used to treat diseases caused by low autoimmunity, especially in relieving fatigue symptoms. It is a superior therapy for CFS in traditional Chinese medicine. At present, there is a lack of the high level clinical evidence to support the moxibustion in the treatment of CFS, so this study will systematically review and analyze the currently available randomized controlled trials to evaluate the efficacy and safety of moxibustion in the treatment of CFS.

METHODS

We will systematically search PubMed, EMBASE, Cochrane library, Sinomed, CNKI, VIP, and Wanfang Database, ClinicalTrials.gov and Chinese Clinical Trial Registry will also be searched. The time range for the search will be from database activation to March 31, 2021. The randomized controlled trials (RCTs) associated with moxibustion for CFS will be included, regardless of language.We will use the standard proposed in Cochrane Handbook 5.1.0 to assess the bias risk of a single RCT. The main outcome index of the study is Fatigue Assessment Instrument (FAI), secondary outcome indexes will include Fatigue Scale -14 (FS-14), Fatigue Severity Scale (FSS), Pittsburgh sleep quality index (PSQI), natural killer (NK) cells, interleukin- 2 (IL-2), T lymphocyte subsets (CD4+, CD8+), cure rate, total efficiency and adverse reactions. The random effect model meta was used to analyze the effect data of a single RCT. Heterogeneity will be measured by Cochran Q test and I-squared statistics. We will use 2 subgroup analyses to explore the source of heterogeneity. RCTs with high bias risk was excluded and adjustment effect model was used for sensitivity analysis to test the robustness of the meta-analysis results. The publication bias included in RCTs will be assessed by funnel plot and Egger test.

RESULTS

This study will objectively and comprehensively evaluate the efficacy and safety of randomized controlled trials of moxibustion in the treatment of chronic fatigue syndrome, and the results will be submitted to peer-reviewed journals for publication.

CONCLUSION

This systematic review will provide clinicians with the latest high-quality evidence for the use of moxibustion in the treatment of chronic fatigue syndrome.

INPLASY REGISTRATION NUMBER

INPLASY202140063.

Authors+Show Affiliations

Guizhou University of Traditional Chinese Medicine, Guizhou.Jiangxi University of Traditional Chinese Medicine, Jiangxi, China.Guizhou University of Traditional Chinese Medicine, Guizhou.Guizhou University of Traditional Chinese Medicine, Guizhou.Guizhou University of Traditional Chinese Medicine, Guizhou.Guizhou University of Traditional Chinese Medicine, Guizhou.Guizhou University of Traditional Chinese Medicine, Guizhou.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

33950958

Citation

Xue, Kaiyang, et al. "The Efficacy and Safety of Moxibustion for Chronic Fatigue Syndrome: a Protocol for Systematic Review and Meta-analysis." Medicine, vol. 100, no. 18, 2021, pp. e25742.
Xue K, Wang Y, Wang X, et al. The efficacy and safety of moxibustion for chronic fatigue syndrome: A protocol for systematic review and meta-analysis. Medicine (Baltimore). 2021;100(18):e25742.
Xue, K., Wang, Y., Wang, X., Chen, P., Xiao, C., Fu, J., & Cui, J. (2021). The efficacy and safety of moxibustion for chronic fatigue syndrome: A protocol for systematic review and meta-analysis. Medicine, 100(18), e25742. https://doi.org/10.1097/MD.0000000000025742
Xue K, et al. The Efficacy and Safety of Moxibustion for Chronic Fatigue Syndrome: a Protocol for Systematic Review and Meta-analysis. Medicine (Baltimore). 2021 May 7;100(18):e25742. PubMed PMID: 33950958.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The efficacy and safety of moxibustion for chronic fatigue syndrome: A protocol for systematic review and meta-analysis. AU - Xue,Kaiyang, AU - Wang,Yanping, AU - Wang,Xianzhu, AU - Chen,Pingnan, AU - Xiao,Caihong, AU - Fu,Jing, AU - Cui,Jin, PY - 2021/04/12/received PY - 2021/04/14/accepted PY - 2021/5/5/entrez PY - 2021/5/6/pubmed PY - 2021/5/13/medline SP - e25742 EP - e25742 JF - Medicine JO - Medicine (Baltimore) VL - 100 IS - 18 N2 - BACKGROUND: The pathogenesis of chronic fatigue syndrome (CFS) is not clear. The main purpose of treatment is to improve autoimmune function and relieve fatigue symptoms. Moxibustion is often used to treat diseases caused by low autoimmunity, especially in relieving fatigue symptoms. It is a superior therapy for CFS in traditional Chinese medicine. At present, there is a lack of the high level clinical evidence to support the moxibustion in the treatment of CFS, so this study will systematically review and analyze the currently available randomized controlled trials to evaluate the efficacy and safety of moxibustion in the treatment of CFS. METHODS: We will systematically search PubMed, EMBASE, Cochrane library, Sinomed, CNKI, VIP, and Wanfang Database, ClinicalTrials.gov and Chinese Clinical Trial Registry will also be searched. The time range for the search will be from database activation to March 31, 2021. The randomized controlled trials (RCTs) associated with moxibustion for CFS will be included, regardless of language.We will use the standard proposed in Cochrane Handbook 5.1.0 to assess the bias risk of a single RCT. The main outcome index of the study is Fatigue Assessment Instrument (FAI), secondary outcome indexes will include Fatigue Scale -14 (FS-14), Fatigue Severity Scale (FSS), Pittsburgh sleep quality index (PSQI), natural killer (NK) cells, interleukin- 2 (IL-2), T lymphocyte subsets (CD4+, CD8+), cure rate, total efficiency and adverse reactions. The random effect model meta was used to analyze the effect data of a single RCT. Heterogeneity will be measured by Cochran Q test and I-squared statistics. We will use 2 subgroup analyses to explore the source of heterogeneity. RCTs with high bias risk was excluded and adjustment effect model was used for sensitivity analysis to test the robustness of the meta-analysis results. The publication bias included in RCTs will be assessed by funnel plot and Egger test. RESULTS: This study will objectively and comprehensively evaluate the efficacy and safety of randomized controlled trials of moxibustion in the treatment of chronic fatigue syndrome, and the results will be submitted to peer-reviewed journals for publication. CONCLUSION: This systematic review will provide clinicians with the latest high-quality evidence for the use of moxibustion in the treatment of chronic fatigue syndrome. INPLASY REGISTRATION NUMBER: INPLASY202140063. SN - 1536-5964 UR - https://www.unboundmedicine.com/medline/citation/33950958/The_efficacy_and_safety_of_moxibustion_for_chronic_fatigue_syndrome:_A_protocol_for_systematic_review_and_meta_analysis_ L2 - https://doi.org/10.1097/MD.0000000000025742 DB - PRIME DP - Unbound Medicine ER -